Long-term Clopidogrel vs Aspirin Monotherapy in Coronary Artery Disease Patients With High Ischemic Risk: HOST-EXAM...

An optimal antiplatelet monotherapy agent for stable coronary artery disease (CAD) patients with high ischemic risk (HIR) is lacking. We analyzed the long-term outcomes between aspirin and clopidogrel monotherapy in a population of patients with CAD.

The current study is a post hoc analysis of the HOST-EXAM Extended Study. HIR was defined as having a history of diabetes or chronic kidney disease, combined with at least 1 of the following: left main percutaneous coronary intervention, a bifurcation lesion treated with stents, a total stent length > 60 mm, at least 3 stents implanted, at least 3 lesions treated, or the presence of chronic total occlusion lesions. The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding complications.

Of 4558 patients, the HIR arm included 803 patients and the non-HIR arm included 3755 patients. The primary endpoint was higher in the HIR arm compared with the non-HIR arm (19.4% vs 13.9%, hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.37-1.68, P < 0.001). Clopidogrel monotherapy was associated with a lower risk of the primary endpoint in the HIR arm (16.4% vs 23.2%, HR 0.67, 95% CI 0.49-0.92, P = 0.014) and in the non-HIR arm (12.1% vs 15.7%, HR 0.74, 95% CI 0.64-0.87, P < 0.001). There was no significant interaction between HIR status and antiplatelet strategy (P for interaction = 0.53).

In this long-term follow-up of stable CAD patients, clopidogrel monotherapy demonstrated significant advantages over aspirin in reducing adverse clinical outcomes, regardless of HIR status.

NCT02044250.